"The ultimate read-out for this program will be conducted in primary cells (cells derived directlyfrom a living organism rather than the immortalised laboratory cells used here) and willdemonstrate the absolute numbers of cells that we are able to successfully achieve geneediting in relative to alternative delivery approaches (eg. electroporation and lipid-baseddelivery systems).The primary cells used in this read-out will be the cell type of interest for the exvivo commercial applications of the CRISPR/Cas9 technology and should therefore directlyinform the commercialisation prospects for the program."
Very interesting in the context of the article I posted a link to above.
Tony
PYC Price at posting:
2.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)